ABSTRACT
The separation of enantiomers is a critical area of research, requiring continual development in order to keep pace with the development of new chiral entities designed to affect life processes, particularly in the pharmaceutical and agrochemical arenas. Since 1992, the U.S. Federal Drug Administration and the European Committee for Proprietary Medicinal Products have mandated that the properties of each enantiomer in a racemic mixture must be tested separately for therapeutic and toxic effects before the compound can be considered for marketing as a new drug. A move toward marketing drugs in single enantiomer forms has driven the need to either synthesize enantiomerically pure forms or make available separation strategies that can effectively resolve racemates. Furthermore, recent estimates of sales of chiral compounds in the United States (for all applications) place the value of this
10.1 Introduction ................................................................................................. 181 10.2 Experimental ............................................................................................... 184 10.3 Results and Discussion ............................................................................... 186
10.3.1 Cinchona Alkaloid Carbamates .................................................... 186 10.3.2 Antimony Tartrate ......................................................................... 190
10.4 Conclusion .................................................................................................. 199 Acknowledgments .................................................................................................. 199 References ..............................................................................................................200
